检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres,Larisa Girshova,Vadim A Doronin,Maria Diez-Campelo,David Valcarcel,Suman Kambhampati,Nora-Athina Viniou,Dariusz Woszczyk,Raquel De Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Ciliao Munhoz,Uwe Platzbecker,Valeria Santini,Robert J. Fram,Ying Yuan,Douglas V. Faller,Lionel Ades

Blood（2021）

引用 10|浏览18
暂无评分
摘要
Background:
更多
查看译文
关键词
azacitidine,acute myeloid leukemia,pevonedistat,first-line,higher-risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要